Tarek M. Taha

6 Weizman Street, 6423906
Tel Aviv, TA 64239, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 57 publications

Comparative assessment of METastasis Reporting and Data System for Prostate Cancer versus Prostate Cancer Clinical Trials Working Group 3 Criteria in assessing treatment response in patients with metastatic castration-resistant prostate cancer.

Comparative assessment of METastasis Reporting and Data System for Prostate Cancer versus Prostate Cancer Clinical Trials Working Group 3 Criteria in assessing treatment response in patients with metastatic castration-resistant prostate cancer.

Journal: European urology open science

Published: August 02, 2026

Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.

Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.

Journal: Minerva urology and nephrology

Published: June 23, 2026

DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives.

DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives.

Journal: Drugs

Published: April 16, 2026

Falling-down bladder flap reconstruction for recalcitrant bladder neck contracture: One complex case and stepwise technique.

Falling-down bladder flap reconstruction for recalcitrant bladder neck contracture: One complex case and stepwise technique.

Journal: Urology case reports

Published: March 01, 2026

Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study).

Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study).

Journal: Targeted oncology

Published: February 20, 2026

Belzutifan monotherapy and combination therapies in renal cell carcinoma: a clinical trial perspective from the ARON working group.

Belzutifan monotherapy and combination therapies in renal cell carcinoma: a clinical trial perspective from the ARON working group.

Journal: Expert opinion on pharmacotherapy

Published: February 04, 2026

An agent-based learning model integrating sex differences in renal cell carcinoma.

An agent-based learning model integrating sex differences in renal cell carcinoma.

Journal: Frontiers in immunology

Published: January 02, 2026

Global Real-World Outcomes of Olaparib in Metastatic Castration-Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations.

Global Real-World Outcomes of Olaparib in Metastatic Castration-Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations.

Journal: International journal of cancer

Published: December 24, 2025

Microplastics as both a driver of genitourinary cancers and a deliverer of treatments.

Microplastics as both a driver of genitourinary cancers and a deliverer of treatments.

Journal: Communications medicine

Published: November 25, 2025

Reply to: Comments on "Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)".

Reply to: Comments on "Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)".

Journal: International journal of cancer

Published: November 15, 2025

Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study.

Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study.

Journal: JCO global oncology

Published: October 29, 2025

Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort.

Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort.

Journal: European urology open science

Published: October 16, 2025

Showing 1-12 of 57

Last Updated: 09/26/2026